The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Feature|Articles|April 2, 2024
- Pharmaceutical Technology, April 2024
- Volume 48
- Issue 4
- Pages: 12
Digital Valve Controller for Control and On-off Valves
Author(s)Pharmaceutical Technology Editors
Emerson’s Fisher FIELDVUE DVC7K Digital Valve Controller provides local analysis of valve data and digital communications with host systems, as well as other features.
Emerson’s Fisher FIELDVUE DVC7K Digital Valve Controller is a new digital valve controller featuring Emerson’s Advice at the Device technology. Digital valve controllers are accessories for control and on-off valves are used to provide local analysis of valve data and digital communications with host systems, as well as other features. These features improve uptime by alerting personnel to developing problems, reducing maintenance costs by providing information required for proactive rather than reactive maintenance, and cutting troubleshooting time in the event of an issue by providing recommended corrective actions.
The DVC7K ‘s Advice at the Device technology contains embedded computing and real-time analytics that convert raw data into information with Bluetooth capability. This allows maintenance personnel to receive data via their phone, tablet, or computer wirelessly without having to be in a control room at the plant location. Information can be accessed wirelessly from one or more digital valve controllers from up to 30 ft, and the local user interface displays detailed information via LEDs.
Articles in this issue
over 2 years ago
The Growing Future of Drug Manufacturingover 2 years ago
Steps Towards Demystifying Risk-Based Decision Makingover 2 years ago
Development of Mini-Tablet and Multi-Unit Pellet Systemsover 2 years ago
Innovations in Prefilled Biologicsover 2 years ago
Testing the Limits of Extractables and Leachablesover 2 years ago
Making Lifecycle Management More Efficient in Europeover 2 years ago
Taking Full Advantage of Service Providersover 2 years ago
Looking at the Potential Impact of JCA on Pharmaover 2 years ago
Streamlining Variationsover 2 years ago
May I Present the NeoantigenRelated to this article
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.